外泌体miRNA在肝细胞癌中的研究进展

张天红; 杨红菊

doi:10.12259/j.issn.2095-610X.S20220221

外泌体miRNA在肝细胞癌中的研究进展

doi: 10.12259/j.issn.2095-610X.S20220221

张天红^{1, 2},
杨红菊^{1, 2, ,}

1.
云南省保健康复中心康复医学科，云南昆明　650307
2.
昆明医科大学第一附属医院干疗消化科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（81660410）；云南省科技厅昆医联合重点专项（2017FE468（-174））

详细信息

作者简介:
张天红（1981～），女，学士，主治医师，主要从事临床内科工作

通讯作者:
杨红菊，E-mail：1379702184@qq.com

中图分类号: R3
计量
- 文章访问数: 3813
- HTML全文浏览量: 2341
- PDF下载量: 33
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-13
- 网络出版日期: 2022-02-24
- 刊出日期: 2022-03-04

Research Progress of Exosomal miRNA in Hepatocellular Carcinoma

Tianhong ZHANG^{1, 2},
Hongju YANG^{1, 2
, ,}

1.
Dept. of Rehabilitation Medicine，Yunnan Health Rehabilitation Center，Yunnan 650307
2.
Dept. of Geriatric Gastroenterology，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650000，China

摘要

摘要: 外泌体是一种由不同细胞分泌的囊泡小体，它通过多种机制促进肝癌的发生发展，目前对于外泌体miRNA在肝癌中作用的研究引起了广泛关注；并根据外泌体miRNA的特性，从而更好地了解肝癌的发生机制，这对肝癌的诊断、治疗有重要意义。对外泌体miRNA在肝细胞癌发展过程中的相关研究进展作一综述。
- 肝细胞癌 /
- 外泌体 /
- miRNA
Abstract: Exosomes are vesicle bodies secreted by different cells, which promote the occurrence and development of liver cancer through various mechanisms.At present, studies on the role of exosomal miRNA in liver cancer have aroused wide attention.According to the characteristics of exosomal miRNA, the pathogenesis of liver cancer can be better understood, which is of great significance for the diagnosis and treatment of liver cancer.In this paper, the research progress of exosomal miRNA in the development of hepatocellular carcinoma is reviewed.
- Hepatocellular carcinoma /
- Exosomes /
- miRNA

HTML全文

参考文献(35)

[1]	Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer Journal for Clinicians,2018,68(6):394-424. doi: 10.3322/caac.21492
[2]	Navin P J,Venkatesh S K. Hepatocellular carcinoma:State of the art imaging and recent advances[J]. Clin Transl Hepatol,2019,7:72-85.
[3]	Sasaki R,Kanda T,Yokosuka O,et al. Exosomes and hepatocellular carcinoma:From bench to bedside[J]. Int J Mol Sci,2019,20(6):1406. doi: 10.3390/ijms20061406
[4]	Tsuchiya A,Ogawa M,Watanabe T,et al. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma[J]. Heliyon,2019,5:1325.
[5]	Nojehdehi S,Soudi S,Hesampour A,et al. Immunomodulatory effects of mesenchymal stem cell–derived exosomes on experimental type-1 autoimmune diabetes[J]. J Cell Biochem,2018,119(11):9433-9443. doi: 10.1002/jcb.27260
[6]	Lal C V,Olave N,Travers C,et al. Exosomal microRNA predicts and protects against severe bronchopulmonary dysplasia in extremely premature infants[J]. JCI Insight,2018,3(5):116-119.
[7]	An M,Zhu J,Wu J,et al. Circulating exosomes from pancreatic Cancer Accelerate the migration and proliferation of PANC-1 cells[J]. J Proteome Res,2018,17(4):1690-1699.
[8]	Rao P S S,O’Connell K,Finnerty T K. Potential role of extracellular vesicles in the pathophysiology of drug addiction[J]. Mol Neurobiol,2018,55(8):6909-6913.
[9]	Fan Q,Yang L,Zhang X,et al. The emerging role d exosome-derived non-coding RNAs in cancer biology[J]. Cancer Letter,2018,414:107-115. doi: 10.1016/j.canlet.2017.10.040
[10]	Fu X,Liu M,Qu S,et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/AKt pathway[J]. J Exp Clin Cancer Res,2018,37:52. doi: 10.1186/s13046-018-0677-7
[11]	Ye L,Zhang Q,Cheng Y,et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion[J]. Immunother Cancer,2018,6:145. doi: 10.1186/s40425-018-0451-6
[12]	Rao Q,Zou B,Lu Z,et al. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro[J]. Hepatology,2016,64:456-472. doi: 10.1002/hep.28549
[13]	Lin X J,Fang J H,Yang X J,et al. Hepatocellular carcinoma cell-secreted exosomal microRNA-210 promotes angiogenesis invitro and invivo[J]. Mol Ther Nucleic Acids,2018,11(6):243-252.
[14]	Chen L,Han Y,Li Y J,et al. Hepatocyte-derived exosomal MiR-194 activates PMVECs and promotes angiogenesis in hepatopulmonary syndrome[J]. Cell Death and Disease,2019,10:853. doi: 10.1038/s41419-019-2087-y
[15]	Yusuke Matsuura,Hiroshi Wada,Hidetoshi Eguchi,et al. Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells[J]. Digestive Diseases and Sciences,2019,64(3):792-802.
[16]	Cao L Q,Yang X W,Chen Y B,et al. Exosomal miR-21 regulates the TETs/ PTENp1/PTEN pathway to promote hepatocellular carcinoma growth[J]. Molecular Cancer,2019,18:148. doi: 10.1186/s12943-019-1075-2
[17]	Yi P S,Li J S. High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma[J]. Mol Clin Oncol,2018,8(6):733-739.
[18]	Hung J H,Li C H,Yeh C H,et al. MicroRNA-224 down-regulates Glycine N-methyltransferase gene expression in Hepatocellular Carcinoma[J]. Sci Rep,2018,8:12284. doi: 10.1038/s41598-018-30682-5
[19]	Tang J,Li Y,Liu K,et al. Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma[J]. Minerva Med,2018,109(1):15-23.
[20]	Li B,Mao R,Liu C,et al. LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells[J]. Life Sci,2018,197:122-129. doi: 10.1016/j.lfs.2018.02.006
[21]	Fang T,Lv H,Lv G,et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer[J]. Nat Commun,2018,9(1):191.
[22]	Ulrich H Weidle,Daniela Schmid,Fabian Birzele,et al. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma:Target Candidates,Functionality and E fficacy in Animal Models and Prognostic Relevance[J]. Cancer Genomics & Proteomics,2020,17:1-21.
[23]	Chu Y,Fan W,Guo W,et al. miR-1247-5p functions as a tumor suppressor in human hepatocellular carcinoma by targeting Wnt3[J]. Oncol Rep,2017,38:343-351. doi: 10.3892/or.2017.5702
[24]	Li D P,Fan J,Wu Y J,et al. MiR-155 up-regulated by TGF-β promotes epithelial-mesenchymal transition,invasion and metastasis of human hepatocellular carcinoma cells in vitro[J]. Am J Transl Res,2017,9(6):2956-2965.
[25]	Fu X,Wen H Q,Jing L,et al. MicroRNA‐155‐5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway[J]. Cancer Sci,2017,108(4):620-631. doi: 10.1111/cas.13177
[26]	Lian J,Jing Y,Dong Q,et al. miR - 192,a prognostic indicator,targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma[J]. Oncotarget,2016,7:2672-2683. doi: 10.18632/oncotarget.6603
[27]	Fang J H,Zhang Z J,Shang L R,et al. Hepatomacell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins[J]. Hepatology,2018,68(4):1459-1475. doi: 10.1002/hep.29920
[28]	Liu J,Fan L,Yu H,et al. Endoplasmic Reticulum Stress Promotes Liver Cancer Cells to Release Exosomal miR-23a-3p and Upregulate PD-L1 Expression in Macrophages[J]. Hepatology,2019,70(1):241-258.
[29]	Wang X,Liu S S,Cao L,et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma[J]. Oncotarget,2017,8(49):86592-86603. doi: 10.18632/oncotarget.21246
[30]	Ye W K,Li J K,Fang G,et al. Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma:Association between clinicopathological features and prognosis[J]. Oncol Lett,2018,15(5):7255-7264.
[31]	Shi M,Jiang Y,Yang L,et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma[J]. J Cell Biochem,2018,119(6):4711-4716.
[32]	Cheng J W,Chen Y K,Zhao P,et al. Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance[J]. Oncol Lett,2017,13(5):3859-3865. doi: 10.3892/ol.2017.5882
[33]	Huang Y H,Liang K H,Chien R N,et al. A circulating microRNA signature capable of assessing the risk of hepato-cellular carcinoma in cirrhotic patients[J]. Sci Rep,2017,7:523. doi: 10.1038/s41598-017-00631-9
[34]	Sun W,Luo J D,Jiang H,et al. Tumor exosomes:a double-edged sword in cancer therapy[J]. Acta Pharmacol Sin,2018,39(4):534-541. doi: 10.1038/aps.2018.17
[35]	Ebrahimkhani S,Vafaee F,Young P E,et al. Exosomal microRNA signatures in multiple sclerosis reflect disease status[J]. Sci Rep,2017,7:14293. doi: 10.1038/s41598-017-14301-3

相关文章(20)

[1]	朱磊, 李瑞雪, 鲍长磊, 黄晨宸, 梁书鑫, 赵振林, 朱洪. MSC-exo一种新型细胞递送工具转运靶向基因调控胰腺癌增殖效应分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240206
[2]	陈杭, 崔琦, 黄敏杉, 刘建军, 马岚青. miRNA在非酒精性脂肪性肝病中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240101
[3]	陈怡璇, 王琳, 夏秀宏, 彭在坤, 丁奕, 史润娇, 雷学芬. 自噬在肝细胞癌中的作用机制研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230416
[4]	张明, 于成龙, 曹锦鹏. ZNF384调控GCLM对肝细胞癌转移的机制研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231108
[5]	曹诗杰, 安红伟. MSC来源外泌体治疗缺血性脑卒中机制及进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230913
[6]	张梁, 王保全, 雷喜锋, 王旭, 柯阳, 张玮. M2巨噬细胞来源的外泌体miR-1246调控胃癌细胞的生长和侵袭, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230724
[7]	付海艳, 闫俊芳, 李红娟, 王霖, 张洁, 周宇君, 徐斌, 罗煜. 时间间隔对肝动脉化疗栓塞术序贯微波消融治疗肝细胞癌的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221127
[8]	顾君, 何泽喜, 栾婷, 王海峰, 王剑松, 丁明霞. 外泌体长链非编码RNA在膀胱癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220110
[9]	曹凡, 刘阳文, 魏雷, 谢楠, 杨裔坚, 钱程, 李春满, 付必莽, 胥江品, 阎容稷, 曾汪. 乙型肝炎病毒与肝细胞癌微血管侵犯的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210331
[10]	马丽娅, 饶南荃, 杨禾丰. 间充质干细胞外泌体在口腔组织再生中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210527
[11]	蔡啸, 扆雪涛, 姚菁青, 戴昕妤, 汤忠泉, 欧婷, 赵晓敏, 李云涛. 人骨髓间充质干细胞分泌的外泌体调控恶性胶质瘤相关巨噬细胞的极化, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210101
[12]	杨佳, 李娅娴, 王莹莹, 肖琳, 李传印, 谭芳, 马千里, 刘舒媛. 云南汉族人群mircoRNA-149、mircoRNA-219、mircoRNA-let-7基因多态性与非小细胞肺癌发生和发展的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211037
[13]	魏韩笑, 张爱君, 李强, 金培生. 血管内皮祖细胞外泌体调控骨髓间充质干细胞基因表达谱芯片, 昆明医科大学学报.
[14]	贾凤梅, 殷顺会, 冉丽权, 田明彤, 张明珠. 特发性牙龈纤维瘤来源外泌体对正常牙龈细胞周期的影响, 昆明医科大学学报.
[15]	谭骅, 仁虹, 赵玲, 游顶云, 杨亚琛. 行TACE治疗后原发性肝细胞癌患者预后的影响因素, 昆明医科大学学报.
[16]	於晓东, 龙江. 12外泌体对体外血脑屏障模型功能的影响, 昆明医科大学学报.
[17]	雷喜锋, 侯峰强, 刘韬, 张伟. FOXP2抑制人肝细胞癌增殖及其机制, 昆明医科大学学报.
[18]	雷喜锋, 侯峰强, 杨少华, 张伟. miR-373在人肝细胞癌中的表达及其作用, 昆明医科大学学报.
[19]	常国楫, 顾金松, 孙林. MicroRNA在心肌再灌注损伤应用的研究进展, 昆明医科大学学报.
[20]	邱建武. P38MAPK特异性抑制剂SB203580对肝癌细胞增殖的影响, 昆明医科大学学报.